Branimir Ivan Sikic | Academic Influence

Branimir Ivan Sikic's AcademicInfluence.com Rankings

Branimir Ivan Sikic

Medical

#1926

World Rank

#2312

Historical Rank

Oncology

#166

World Rank

#172

Historical Rank

Pharmacology

#305

World Rank

#354

Historical Rank

medical Degrees

Download Badge

Medical

Branimir Ivan Sikic's Degrees

PhD Pharmacology University of California, San Francisco

Why Is Branimir Ivan Sikic Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Branimir Ivan "Brandy" Sikic is an American medical doctor and scientist at Stanford University School of Medicine. He is an oncologist and cancer pharmacologist, and has served as a faculty member at Stanford University since 1979. His research spans basic, translational, and clinical research and investigates the mechanisms of drug resistance and the development of new anticancer therapies.

(See a Problem?)

Branimir Ivan Sikic's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Integrated Genomic Analyses of Ovarian Carcinoma (2011) (6411)
Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. (1999) (559)
Antineoplastic Agents (2003) (521)
Gene expression patterns in ovarian carcinomas. (2003) (333)
Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. (2005) (303)
Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity (1991) (300)
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. (1992) (295)
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein (1997) (290)
Detection of cell-affecting agents with a silicon biosensor. (1989) (282)
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. (2016) (248)
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). (2004) (242)
Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. (1992) (223)
Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. (1985) (222)
Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. (1991) (213)
Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. (1985) (204)
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. (1994) (201)
Modulation of multidrug resistance: at the threshold. (1993) (195)
Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance (2012) (181)
High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. (2005) (175)
Liposomal protection of adriamycin-induced cardiotoxicity in mice. (1980) (171)
Clinical studies with modulators of multidrug resistance. (1995) (165)
Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. (1998) (163)
Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. (1999) (162)
Clinical trials of modulation of multidrug resistance pharmacokinetic and pharmacodynamic considerations (1993) (154)
Pharmacological considerations in the modulation of multidrug resistance. (1996) (146)
NFKBIA deletion in glioblastomas. (2011) (140)
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. (2010) (138)
Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). (1996) (125)
A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors (2014) (125)
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. (2004) (121)
Improved therapeutic index of bleomycin when administered by continuous infusion in mice. (1978) (117)
Tumor Necrosis Factor-α–Induced Protein 3 As a Putative Regulator of Nuclear Factor-κB–Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas (2006) (116)
Multidrug resistance in lymphomas. (1994) (113)
Continuous infusion or bolus injection in cancer chemotherapy. (1983) (113)
Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar) (1999) (111)
Pharmacologic approaches to reversing multidrug resistance. (1997) (111)
A network model of a cooperative genetic landscape in brain tumors. (2009) (110)
Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. (2007) (105)
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. (2005) (102)
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. (2017) (100)
Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion (2004) (100)
Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. (1991) (96)
Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. (1983) (95)
Molecular Targets in Oncology: Implications of the Multidrug Resistance Gene (1993) (92)
Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. (1994) (91)
Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary. (1983) (90)
Multidrug-resistant Human Sarcoma Cells with a Mutant P-Glycoprotein, Altered Phenotype, and Resistance to Cyclosporins* (1997) (89)
Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. (2006) (89)
Pulmonary toxicity of antitumor agents. (1983) (85)
Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. (1995) (85)
Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. (1995) (84)
Biochemical and cellular determinants of bleomycin cytotoxicity. (1986) (84)
Dominant effector genetics in mammalian cells (2001) (84)
Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis (2016) (83)
Conservation of the Class I -Tubulin Gene in Human Populations and Lack of Mutations in Lung Cancers and Paclitaxel-resistant Ovarian Cancers 1 (2002) (81)
Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. (1989) (80)
Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung. (1984) (79)
A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. (2001) (79)
Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. (1986) (79)
Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. (2005) (78)
Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers (2014) (78)
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. (2006) (76)
Mechanisms of Resistance to Cabazitaxel (2014) (74)
Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells. (1995) (73)
Quantification of bleomycin pulmonary toxicity in mice by changes in lung hydroxyproline content and morphometric histopathology. (1978) (73)
The miR‐200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR‐3 and MES‐OV cells (2015) (72)
The effects of α-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice (1979) (68)
Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. (2009) (68)
A therapy planning architecture that combines decision theory and artificial intelligence techniques. (1990) (68)
Modification of cisplatin toxicity with diethyldithiocarbamate. (1990) (65)
Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography. (2002) (65)
Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques. (1994) (62)
Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT). (2011) (61)
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21‐day infusion to patients with advanced ovarian carcinoma (2004) (60)
A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI (2007) (59)
Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. (1995) (59)
Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success? (2008) (57)
Modulation of multidrug resistance: a paradigm for translational clinical research. (1999) (57)
Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA. (2005) (56)
The effects of ascorbic acid deficiency and repletion on pulmonary, renal, and hepatic drug metabolism in the guinea pig. (1977) (55)
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). (1999) (55)
The use of probenecid as a chemoprotector against cisplatin nephrotoxicity (1991) (55)
Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog. (1985) (54)
Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. (2001) (53)
Drug resistance in clinical oncology and hematology. Introduction. (1995) (52)
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. (2009) (51)
Delivery of a normal infant following cisplatin, vinblastine, and bleomycin (PVB) chemotherapy for malignant teratoma of the ovary during pregnancy. (1990) (51)
Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. (2000) (50)
High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group. (1986) (49)
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia (1999) (48)
A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer (2008) (47)
CCAAT/Enhancer-Binding Protein β (Nuclear Factor for Interleukin 6) Transactivates the Human MDR1 Gene by Interaction with an Inverted CCAAT Box in Human Cancer Cells (2004) (47)
A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy. (1991) (47)
Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. (2005) (46)
Identification of ovarian cancer driver genes by using module network integration of multi-omics data (2013) (46)
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). (1999) (46)
Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. (2002) (45)
Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group (2004) (44)
Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells (1992) (44)
Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. (1988) (44)
Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow. (1990) (43)
MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells (2000) (42)
Clinical trial designs for testing biomarker-based personalized therapies (2012) (42)
Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. (1984) (42)
Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. (1992) (42)
Patterns of failure in small cell carcinoma of the lung (1982) (41)
Neurologic dysfunction in patients treated for small cell carcinoma of the lung: a clinical and radiological study. (1986) (41)
Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. (2011) (41)
Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. (1994) (40)
Enhancement of bleomycin activity against Lewis lung tumors in mice by local hyperthermia. (1979) (39)
Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. (2016) (38)
Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. (1997) (38)
Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition (2017) (38)
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. (2020) (38)
A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer (2005) (37)
Late consolidative radiation therapy in the treatment of limited‐stage small cell lung cancer (1991) (36)
Clinical studies of antisense therapy in cancer. (2000) (36)
Adsorption of antineoplastic drugs following large-volume ip administration to rats. (1982) (36)
Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335). (2000) (36)
Effect of whole-body hyperthermia on the disposition and metabolism of adriamycin in rabbits. (1978) (36)
Advanced epithelial ovarian cancer: toxicity of whole abdominal irradiation after operation, combination chemotherapy, and reoperation. (1986) (35)
Preliminary results of concurrent radiotherapy and chemotherapy in advanced cervical carcinoma: a phase I-II prospective intergroup NCOG-RTOG Study. (1990) (34)
Repeat administration of marihuana smoke to humans. (1974) (34)
Differential expression of tubulin isotypes during the cell cycle. (1996) (33)
Phase I study of valspodar (PSC‐833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children's Oncology Group (2010) (33)
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer (2005) (33)
Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia. (1997) (32)
Antibody-directed targeting of liposomes to human cell lines: role of binding and internalization on growth inhibition. (1987) (32)
Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma. (1985) (32)
Anticancer drug discovery. (1991) (32)
HGS-ETR2-A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors. (2006) (30)
Relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomycin A. (1980) (30)
Volume-activated chloride current is not related to P-glycoprotein overexpression. (1994) (30)
DNA cross-linking and cytotoxicity of the alkylating cyanomorpholino derivative of doxorubicin in multidrug-resistant cells. (1988) (29)
Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. (2004) (29)
Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. (1994) (28)
Expression and Silencing of the Microtubule-Associated Protein Tau in Breast Cancer Cells (2010) (28)
Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease (1986) (28)
Association of DNA cross-linking with potentiation of the morpholino derivative of doxorubicin by human liver microsomes. (1989) (27)
Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies. (2014) (27)
Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance (2000) (27)
Hepatic cytochrome P-450-dependent metabolism and enzymatic conjugation of foreign compounds in vitamin A-deficient rats. (1980) (26)
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. (2004) (26)
Chromatin-Remodeling Complex SWI/SNF Controls Multidrug Resistance by Transcriptionally Regulating the Drug Efflux Pump ABCB1. (2016) (26)
A Pilot Phase II Trial of Valspodar Modulation of Multidrug Resistance to Paclitaxel in the Treatment of Metastatic Carcinoma of the Breast (E1195): A Trial of the Eastern Cooperative Oncology Group (2006) (26)
Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug‐resistant variants of a human sarcoma (2002) (25)
Second-look laparotomy in epithelial ovarian carcinoma: precise definition, sensitivity, and specificity of the operative procedure. (1984) (24)
A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). (2006) (24)
CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. (2004) (23)
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. (2005) (21)
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. (2003) (20)
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies (2006) (19)
Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors (2011) (19)
Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe. (2018) (19)
GLUTATHIONE S-TRANSFERASES P, ALPHA, MU, AND MDR1 MRNA EXPRESSION IN NORMAL LYMPHOCYTES AND CHRONIC LYMPHOCYTIC LEUKEMIA (1995) (19)
Characterization and immunoassay of human tumor-associated galactosyltransferase isoenzyme II. (1988) (18)
Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole. (1988) (18)
Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumours? (2004) (17)
A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM) (2008) (17)
Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin. (1990) (16)
New approaches in cancer treatment. (1999) (16)
Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer (2008) (16)
Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results. (2018) (16)
Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors. (2007) (16)
Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism. (1992) (16)
Identification of ovarian cancer driver genes by using module network integration of multi-omics data (2014) (15)
In vitro selection and characterization of a bleomycin-resistant subline of B16 melanoma. (1986) (15)
A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors (2008) (15)
Doxorubicin selection for MDR1/P-glycoprotein reduces swelling-activated K+ and Cl- currents in MES-SA cells. (1996) (15)
Multidrug Resistance and Stem Cells in Acute Myeloid Leukemia (2006) (14)
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer (2012) (14)
Central nervous system toxicity and cerebrospinal fluid pharmacokinetics of intraventricularly administered bleomycin in beagles. (1985) (14)
Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors. (2014) (14)
Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. (2009) (14)
Assessment of purging with multidrug resistance (MDR) modulators and VP-16: results of long-term marrow culture. (1990) (14)
A method for detecting and correcting feature misidentification on expression microarrays (2004) (13)
ONYX: An Architecture for Planning in Uncertain Environments (1985) (13)
Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicin. (1992) (13)
In vitro drug metabolism in male and female athymic, nude mice. (1978) (13)
Bleomycin, mitomycin, and cisplatin therapy for advanced squamous carcinoma of the uterine cervix: a phase II study of the Northern California Oncology Group. (1985) (13)
Effects of dietary ascorbic acid supplementation on hepatic drug-metabolizing enzymes in the guinea pig. (1977) (12)
Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model. (1992) (12)
A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors. (2018) (12)
Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues (1996) (12)
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies (2011) (12)
Re: Genetic Analysis of the β-Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer (2002) (12)
Doxorubicin and the alkylating anthracycline 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin: comparative in vitro potency against leukemia and bone marrow cells. (1988) (12)
A phase I study of the VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK 222584) and gemcitabine in patients with advanced pancreatic cancer. (2006) (11)
Differential Gene Expression Patterns and Interaction Networks in BCR/ABL Positive and Negative Adult Acute Lymphoblastic Leukemias. (2006) (11)
Methodologic problems in clonogenic assays of spontaneous human tumors (2004) (11)
An Evaluation of a Program for the Treatment of Alcoholism in Croatia (1972) (11)
222 A first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with advanced solid tumors (2010) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Cyclosporin A and cyclosporin SDZ PSC 833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells. (1994) (10)
Chapter 17 – POCC VERSUS POCC/VAM THERAPY FOR SMALL-CELL ANAPLASTIC (OAT CELL) LUNG CANCER (1981) (9)
Chapter 49 – Natural and Acquired Resistance to Cancer Therapies (2008) (9)
Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the Ovarian Data Set From The Cancer Genome Atlas. (2018) (9)
Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors. (2010) (9)
An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancer (2008) (9)
Pharmacokinetics of Hu5F9-G4, a first-in-class anti-CD47 antibody, in patients with solid tumors and lymphomas. (2018) (9)
Abstract 1304: Clinical pharmacokinetics of GDC-0973, an oral MEK inhibitor, in cancer patients: data from a Phase 1 study (2011) (9)
A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors (2013) (9)
A regulatory network of canonical nuclear factor-κB activation predicts high-grade glioma outcome (2007) (8)
Advanced epithelial ovarian cancer: Preliminary results of whole abdominal irradiation for patients with recurrent or persistent disease after chemotherapy (1984) (8)
Pulmonary disease as a complication of chlorozotocin chemotherapy. (1981) (8)
Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. (2005) (8)
Glutathione-S-transferases pi, alpha, mu and mdr1 mRNA expression in normal lymphocytes and chronic lymphocytic leukemia. (1995) (8)
Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P‐glycoprotein modulation in acute myeloid leukemia (2018) (8)
Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. (2003) (8)
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors (2022) (8)
Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. (1992) (7)
Genomics of childhood leukemias: the virtue of complexity. (2008) (7)
Clinical reversal of multidrug resistance. (1994) (6)
Abstract 4412:In vitroactivity of the novel tubulin active agent BAL27862 inMDR1(+) andMDR1(−) human breast and ovarian cancer variants selected for resistance to taxanes (2010) (6)
Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin (2000) (6)
Diagnostic accuracies of clinical studies in patients with small cell carcinoma of the lung. (1983) (6)
Purging multidrug resistant cells from bone marrow. (1992) (5)
The reversal of multidrug resistance. (1995) (5)
A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies (2005) (5)
Human tumor clonogenic assays (1981) (5)
The effects of alpha-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice. (1979) (5)
Differential protective effects of varying degrees of hypoxia on the cytotoxicities of etoposide and bleomycin (2004) (5)
Abstract PR13: The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies (2016) (5)
A phase I clinical study of HGS-ETR2, a fully-human monoclonal antibody to TRAIL-R2 in patients with advanced solid tumors (2005) (4)
Introduction to Chemotherapy (2003) (4)
A phase I study of paclitaxel (taxol®) (T) in combination with SDZ PSC 833, a potent modulator of multidrug resistance (MDR): 99 (1994) (4)
Phase I Trial of Uracil–Ftorafur, Leucovorin, and Etoposide: An Active All-oral Regimen for Metastatic Breast Cancer (2003) (4)
371 Phase 2 randomized discontinuation trial (RDT) of XL184 in patients (pts) with advanced solid tumors (2010) (4)
The effect of oral SDZ PSC 833 on the pharmacokinetics (PK) of etoposide (E) during a phase I trial to modulate multidrug resistance: 102 (1994) (4)
Phase I/II Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Pgp-Positive Acute Myeloid Leukemia (AML). (2007) (4)
NFKBIA deletion in triple-negative breast cancer. (2013) (4)
Abstract 831: BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab (2014) (3)
Theoretical, Clinical, and Pharmacokinetic Aspects of Cancer Chemotherapy Administered by Continuous Infusion (1986) (3)
Cyclosporine A increases serum cortisol levels in rabbits. (1995) (3)
DIFFERENTIAL INFLUENCE OF PHYSIOLOGICAL, PHARMACOLOGICAL AND PATHOLOGICAL ALTERATIONS ON HEPATIC AND EXTRAHEPATIC DRUG METABOLISM (1977) (3)
Significance of MicroRNAs in determining taxane resistance in ovarian cancer (2012) (3)
A phase I study with exploratory pharmacodynamic endpoints of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (2007) (3)
Abstract 4001: The anti-CD47 antibody Hu5F9-G4 activates macrophages and inhibits ovarian cancer xenografts, alone and in combination with chemotherapy or immunotherapy (2016) (3)
Analysis of intracellular retention of morpholinyl anthracyclines in multidrug-resistant cancer-cells by interactive laser cytometry. (1994) (3)
Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow (2004) (3)
A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies (2005) (3)
Abstract 817: Enhancement of paclitaxel and carboplatin therapy by CCL2 blockade in ovarian cancers (2012) (2)
Phase I/II Pharmacodynamic Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Acute Myeloid Leukemia (AML). (2006) (2)
Clinical and pathological correlation in oat cell carcinoma of the lung (1981) (2)
342 POSTER A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally to patients with advanced solid malignancies (ASM) (2006) (2)
Abstract 3496: SYK inhibition results in increased sensitivity of OVCAR-3 cells to paclitaxel (2010) (2)
The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance (2019) (2)
A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors (2013) (2)
Chapter 2 – CLINICAL PHARMACOLOGY OF BLEOMYCIN* (1985) (2)
Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421. (2006) (2)
Abstract 1401: SYK promotes tumor progression in ovarian cancer cell lines (2011) (2)
A phase I study of an oral formulation of ixabepilone (ixa) in patients with advanced cancer. (2010) (2)
Preliminary results of concurrent radiotherapy and chemotherapy in advanced cervical carcinoma: A phase I–II prospective intergroup study NCOG‐RTOG (1991) (2)
Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421. (2005) (2)
Mitoxantrone, Etoposide and Cyclosporine A Therapy for Relapsed and Refractory Acute Myelogenous Leukemia, A Pediatric Oncology Group Phase II Trial (1996) (2)
The Rational Basis for Cancer Chemotherapy (2003) (2)
Tumor necrosis factor-α-induced protein 3 down-regulates nuclear factor-κB-mediated drug resistance in vitro and is a favorable clinical prognostic factor in human glioblastomas. (2006) (2)
The distribution of 14C-imipramine in mice bearing Lewis lung carcinoma. (1979) (2)
Abstract 1526: Epithelial mesenchymal transition (EMT) is associated with non-transporter resistance to taxanes in human ovarian cancer cell (2010) (2)
A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies (2018) (2)
6. Advanced Epithelial Ovarian Cancer: Whole Abdominal Irradiation for Patients with Recurrent or Persistent Disease following Chemotherapy (1985) (2)
Phase 2 Randomized Discontinuation Trial of XL184 in Patients with Advanced Solid Tumors (2010) (2)
Re: genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. (2002) (2)
Pharmacokinetic effects of modulation of multidrug resistance: 162 (1994) (1)
The Genomic Stability at the Coding Regions of the Multidrug Transporter Gene ABCB1: Insights into the Development of Alternative Drug Resistance Mechanisms in Human Leukemia Cells (2019) (1)
Discovery ression and Silencing of the Microtubule-Associated Ther tein Tau in Breast Cancer Cells (2010) (1)
Tumor necrosis factor-{alpha}-induced protein 3 down-regulates nuclear factor-{kappa}B-mediated drug resistance in vitro and is a favorable clinical prognostic factor in human glioblastomas (2006) (1)
Pharmacokinetics (PK) and pharmacodynamics (PD) of SDZ PSC 833, a novel multidrug resistance reversing agent, in phase 1 trials with chemotherapeutic agents (1997) (1)
The First Central European Oncology Congress, Opatija, Croatia, 1998 (1999) (1)
CCAAT / Enhancer-Binding Protein ( Nuclear Factor for Interleukin 6 ) Transactivates the Human MDR 1 Gene by Interaction with an Inverted CCAAT Box in Human Cancer Cells (2003) (1)
Reply to D.R. Catchpoole et al (2010) (1)
Chapter 20 – PULMONARY TOXICITY OF BLEOMYCIN* (1985) (1)
FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421. (2004) (1)
Combined chemotherapy and radiotherapy for advanced-stage carcinomas of the cervix. (1992) (1)
ISIS 3521/CGP 64128A- antisense to protein kinase C-alpha (1997) (1)
889 – STUDIES ON THE INTERACTION BETWEEN ADRIAMYCIN AND α-TOCOPHEROL IN VIVO (1978) (0)
Characteristics of a phase II study that predict for a positive phase III trial—A study of 383 clinical trials (2007) (0)
Subject Index, Vol. 21, 1980 (1980) (0)
Effect of cyclosporine on serum cortisol levels in rabbits: 38 (1994) (0)
Predictors for Success in a Phase III Trial—an Analysis of 315 Phase II Chemotherapy Trials for Advanced Cancers (2007) (0)
Lack of correlation between cortisol-induced precocious maturation of the fetal rabbit lung and drug metabolism. (1979) (0)
Modulation of Classical Multidrug Resistance and Drug Resistance in General (2019) (0)
Multidrug Resistance Reversal Utilizing Mitoxantrone, Etoposide and Continuous Infusion Cyclosporine in Pediatric ANLL (1994) (0)
Paclitaxel (Taxol) Resistance in Breast Cancer Cells (1998) (0)
Central European Oncology Congress, June 23-26, 1998, Opatija, Croatia : selected papers (1999) (0)
Concomitant resistance to paclitaxel in an ovarian cancer cell variant selected with carboplatin (2019) (0)
TNFAIP3/A20 as a potential regulator of NF-κB-mediated resistance to O6-alkylating chemotherapy in glioblastoma multiforme (2006) (0)
Array CGH Discovers Novel Genomic Signatures in De Novo Acute Myeloid Leukemia (AML): Results of Children’s Oncology Group (COG) Study POG #9421. (2005) (0)
Abstract 901: Overexpression of inhibitors of apoptosis (IAP) family members in human breast and ovarian cancer models of non-MDR1taxane resistance. (2013) (0)
Osteonectin/SPARC Is Epigenetically Silenced in AML with MLL Gene Rearrangements and Selectively Inhibits the Growth of MLL Rearranged Cell Lines. (2004) (0)
Abstract 2140: Cabazitaxel is more active than first generation taxanes inABCB1(+) cell lines due to its higher intracellular accumulation and reduction in ATPase stimulation (2016) (0)
CD47 antibody blockade as novel therapy for ovarian and breast cancer (2014) (0)
Prognostic effect of EIF4EBP1 on ovarian cancer: A single gene biomarker for overall survival and platinum response. (2013) (0)
SC14.04 The CD47 Macrophage Checkpoint as a New Immunotherapy Target (2017) (0)
Upregulation of miRNA-200 family members in human paclitaxel resistant OVCAR-3/TP cells alters the sensitivity to carboplatin, but not paclitaxel (2013) (0)
Treatment of Poor Prognosis Acute Myelogenous Leukemia with PSC-833 and Mitoxantrone, Etoposide, Cytarabine (1998) (0)
High-resolution profiling of the human glioma genome (2005) (0)
apid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet – visible high-performance liquid chromatography * (2002) (0)
DAMD 1794-J-4352 ' ITLE : Paclitaxel ( Taxol ) Resistance in Breast Cancer Cells (0)
Modulation of VP-16 citotoxicity by verapamil or cyclosporine in MDR cell lines and normal bone marrow (1991) (0)
Abstract C29: Elevated CDKN1A (p21) expression in human cancer cell variants selected for resistance to the novel microtubule depolymerizing agent BAL27862 (active moiety of BAL101553). (2011) (0)
A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients with advanced solid malignancies (ASM) (2007) (0)
ENHANCEMENT OF THE EFFECT OF BLEOMYCIN BY LOCAL HYPERTHERMIA ON LEWIS LUNG TUMORS IN MICE. (1979) (0)
Molecular Cancer apeutics apeutic Discovery ression and Silencing of the Microtubule-Associated Ther tein Tau in Breast Cancer Cells (2010) (0)
Antitumor antibiotics. (1989) (0)
Abstract LB-351: Comprehensive miRNA profiling of taxane-resistant human breast cancer variants using the SmartChip Real-Time PCR System (2011) (0)
The interaction of flurazepam with diphenylhydantoin in the rat. (1976) (0)
In vitro hepatic drug metabolism and enzyme induction in nude athymic mice. Abstr. (1977) (0)
CCAAT/Enhancer-Binding Protein (cid:1) (Nuclear Factor for Interleukin 6) Transactivates the Human MDR 1 Gene by Interaction with an Inverted CCAAT Box in Human Cancer Cells (2004) (0)
Bleomycin hydrolase kinetics in the cytosol of malignant and normal tissues. Abstr. (1981) (0)
Overexpression of inhibitors of apoptosis (IAP) family members in human breast and ovarian cancer models of non-MDR1 taxane resistance (2015) (0)
Gene copy number alterations and differential gene expression in the acquired resistance of ovarian cancer cells to taxanes (2006) (0)
Abstract 763: Resistance to cabazitaxel is associated withABCB1/P-glycoprotein activation, alterations in β-tubulin content and dynamics, reduced BRCA1, and a mesenchymal phenotype in MCF-7 human breast cancer variants (2014) (0)
Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421. (2004) (0)
Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cells (2020) (0)
Population pharmacokinetic modeling of the interaction between the P‐glycoprotein inhibitor PSC‐833 and mitoxantrone in pediatric leukemia patients (2005) (0)
893 High-resolution Mapping of Human Glioma Genomes. (2005) (0)
APhase II Study of Gefitinib , 5-Fluorouracil , Leucovorin , and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer (2008) (0)
Central Nervous System Toxicity and Cerebrospinal Fluid Pharmacokinetics of Intraventricularly Administered Bleomycin in Beagles1 (2006) (0)
Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With (1999) (0)
Abstract 1280: Preclinical and Clinical Evidence for MEK Pathway Inhibition by GDC-0973 using FDG-PET (2011) (0)
50: Proffered Paper: Overcoming immune evasion in ovarian and breast cancer with anti-CD47 antibody blockade: A novel class of immune therapy (2014) (0)
Contents, Vol. 21, 1980 (1980) (0)
Frequently deleted genes in ovarian cancer as indicators of platinum response. (2013) (0)
Development and Characterization of a Human Sarcoma Cell Line, MES-SA, Sensitive to Multiple Drugs1 (2006) (0)
Abstract 4672: Tumor dihydropyrimide dehydrogenase (DPYD) expression is associated with survival in patients with metastatic colorectal cancer treated with gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin (IFOX) (2010) (0)
Abstract 1095: Comprehensive miRNA profiling of taxane-resistant human breast and ovarian cancer cell lines using the SmartChip real-time PCR system (2012) (0)
Effects of schedules of administration of bleomycin on therapy of lewis lung carcinoma and pulmonary toxicity in mice. Abstr. (1978) (0)

This paper list is powered by the following services:

Other Resources About Branimir Ivan Sikic

en.wikipedia.org

What Schools Are Affiliated With Branimir Ivan Sikic?

Branimir Ivan Sikic is affiliated with the following schools:

Image Attributions

Image Source for Branimir Ivan Sikic